C12N 2760/10011
Arenaviridae
C12N2760/10011 (Arenaviridae) appears on 160 US grants and 245 published applications in this corpus.
Search patents in C12N- Granted patents
- 160
- Published applications
- 245
- Assignees
- 129
- Inventors
- 451
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 9 | 0 |
| 1999 | 5 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 0 |
| 2002 | 5 | 4 |
| 2003 | 6 | 6 |
| 2004 | 1 | 3 |
| 2005 | 2 | 6 |
| 2006 | 5 | 8 |
| 2007 | 3 | 4 |
| 2008 | 3 | 4 |
| 2009 | 4 | 3 |
| 2010 | 2 | 10 |
| 2011 | 3 | 6 |
| 2012 | 2 | 10 |
| 2013 | 3 | 3 |
| 2014 | 7 | 16 |
| 2015 | 4 | 7 |
| 2016 | 6 | 11 |
| 2017 | 9 | 8 |
| 2018 | 7 | 12 |
| 2019 | 1 | 14 |
| 2020 | 9 | 12 |
| 2021 | 7 | 18 |
| 2022 | 9 | 19 |
| 2023 | 11 | 11 |
| 2024 | 9 | 17 |
| 2025 | 8 | 22 |
| 2026 | 3 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/10111DeltavirusIndexing code58
- C12N 2760/10034Use of virus or viral component as vaccineIndexing code57
- C12N 2760/10022New viral proteins or individual genes, new structural or functional aspects ofIndexing code43
- C12N 2760/10041Use of virus, viral particle or viral elements as a vectorIndexing code25
- C12N 2760/10032Use of virus as therapeutic agent, other than vaccineIndexing code13
- C12N 2760/10061Methods of inactivation or attenuationIndexing code13
- C12N 2760/10021Viruses as suchIndexing code12
- C12N 2760/10051Methods of production or purification of viral materialIndexing code8
All 13 subgroupsShow fewer
- C12N 2760/10033Use of viral protein as therapeutic agent other than vaccineIndexing code5
- C12N 2760/10023Virus like particles [vlp]Indexing code4
- C12N 2760/10031Uses of virus other than therapeutic or vaccineIndexing code2
- C12N 2760/10071Demonstrated in vivo effectIndexing code2
- C12N 2760/10088For redistributionIndexing code0
Recent patents
- Virus particles for therapeutic purposes18 Aug 2026US 12,708,654 B2Abalos Therapeutics GmbH
- Lassavirus vaccines24 Feb 2026US 12,558,410 B2Katholieke Universiteit Leuven
- VSV chimeric vectors13 Jan 2026US 12,522,844 B2Boehringer Ingelheim International GmbH
- Activation of resident memory T cells for cancer immunotherapy23 Dec 2025US 12,502,406 B2Regents of the University of Minnesota
- Recombinant rhabdovirus encoding for CCL2128 Oct 2025US 12,453,749 B2Boehringer Ingelheim International GmbH
- Vaccines and methods6 Aug 2026US 2026/0224686 A1Cambridge Enterprise Limited
- Compositions and methods for treating viral infections6 Aug 2026US 2026/0226474 A1The University of Sydney
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Multivalent vaccines against tuberculosis30 Jul 2026US 2026/0218232 A1Regents of the University of Minnesota
- Activation of resident memory t cells for cancer immunotherapy28 May 2026US 2026/0144820 A1New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special
Most cited
By later US patents
- 2'-O-amino-containing nucleoside analogs and polynucleotides130US 6,159,951 ARibozyme Pharmaceuticals, Inc. · 2000
- Therapeutic ribozyme compositions and expression vectors92US 5,225,347 AInnovir Laboratories, Inc. · 1993
- Assay for Ribozyme target site58US 5,525,468 ARibozyme Pharmaceuticals, Inc. · 1996
- Synthesis deprotection analysis and purification of RNA and ribozymes56US 5,831,071 ARibozyme Pharmaceuticals, Inc. · 1998
- Synthesis, deprotection, analysis and purification of RNA and ribozymes56US 6,469,158 B1Ribozyme Pharmaceuticals, Inc. · 2002